Kamen Kutzarov
Foot and Ankle Surgery · Austin, TXNPI 1023498268
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (44.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Arthrex at 58.9% of the total. Reporting peaked in 2022 at $11,762 and has fallen 88.7% since, to $1,324 in 2025.
Across 130 payments — averaging $173.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$13K
- Stryker$7K
- Medinc Of Texas$1K
- Smith+Nephew$394
- Ossur Americas, Inc.$239
- Johnson & Johnson$144
- plus $352 from 9 others
What the payments were for
- Grants$10,00044%
- Travel & lodging$2,35110%
- Food & beverage$6,56529%
- Education$3,60016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 14 | $13,259 |
| Stryker | 75 | $6,721 |
| Medinc Of Texas | 3 | $1,406 |
| Smith+Nephew | 5 | $394 |
| Ossur Americas, Inc. | 18 | $239 |
| Johnson & Johnson(2 entities) | 2 | $144 |
| Bone Support Inc. | 1 | $116 |
| Amgen | 5 | $112 |
| Orthofix Medical, Inc. | 1 | $42 |
| UCB, Inc. | 1 | $21 |
| Pfizer | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Core Surgical Group | 1 | $15 |
| Paragon 28, Inc. | 1 | $12 |
| Alafair Biosciences, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$2,026
- INBONE$831
- INFINITY ADAPTIS$441
- AUGMENT INJECTABLE$332
- ORTHOLOC 2 LAPIFUSE$326
- 7 X 23MM CITRELOCK IMPLANT$324
- CITREFIX$324
- PROPHECY$312
- PROstep$304
- AXS INFINITY LS$202
- OMEGA$174
- SONICANCHOR$174
- HOFFMANN$172
- EASYFUSE$166
- Actishield$164
- SALVATION$162
- VALOR$148
- Taylor Spatial Frame$123
- NA$123
- CERAMENTBONE VOID FILLER$116
How this compares
$22,516 in reported general payments places this provider in the 85th percentile of 684 foot and ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 60 | $876 |
| Meloxicam | 141 | $863 |
| Diclofenac Sodium | 23 | $395 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $260 |
| Gabapentin | 43 | $258 |
| Ondansetron Hcl | 40 | $182 |
| Tramadol Hcl | 63 | $153 |
| Methylprednisolone | 24 | $133 |
Paid to pharmacies, not to this prescriber.
Other foot and ankle surgery in Austin
- Mark DaltonAustin$1.9M
- Andrew EbertAustin$82K
- Pedro CosculluelaAustin$69K
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.